ArticleBMC bioinformatics2008
Preferential binding of allosteric modulators to active and inactive conformational states of metabotropic glutamate receptors.
Article in BMC bioinformatics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Crystal structure of the CoV-Y domain of SARS-CoV-2 nonstructural protein 3.Scientific reports · 2023Article
- Structure of the Sec14 domain of Kalirin reveals a distinct class of lipid-binding module in RhoGEFs.Nature communications · 2023Article
- Article
- Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future.Journal of Alzheimer's disease : JAD · 2020Review
- Structural and functional analyses of the N-terminal domain of the A subunit of aProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Characterization of 2-amino-1-methyl-6-phenylimidazo[4,5b]pyridine at androgen receptor: mechanistic support for its role in prostate cancer.American journal of cancer research · 2015Article
- Crystal structure of the catalytic domain of the Bacillus cereus SleB protein, important in cortex peptidoglycan degradation during spore germination.Journal of bacteriology · 2012Article
- Role of a SpoVA protein in dipicolinic acid uptake into developing spores of Bacillus subtilis.Journal of bacteriology · 2012Article
- Identification of motions in membrane proteins by elastic network models and their experimental validation.Methods in molecular biology (Clifton, N.J.) · 2012Article
- A mitochondria-targeted inhibitor of cytochrome c peroxidase mitigates radiation-induced death.Nature communications · 2011Article
- Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides.Current cancer drug targets · 2011Article
- Investigation on quantitative structure activity relationships and pharmacophore modeling of a series of mGluR2 antagonists.International journal of molecular sciences · 2011Article
- Allosteric Modulation of G Protein Coupled Receptors by Cytoplasmic, Transmembrane and Extracellular Ligands.Pharmaceuticals (Basel, Switzerland) · 2010Article
- Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase.Current cancer drug targets · 2010Review
- Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation.Nature nanotechnology · 2010Article
- The importance of valine 114 in ligand binding in beta(2)-adrenergic receptor.Protein science : a publication of the Protein Society · 2010Article
- Bioinformatics research in the Asia Pacific: a 2007 update.BMC bioinformatics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Metabotropic glutamate receptors (mGluRs) are G protein coupled receptors that play important roles in synaptic plasticity and other neuro-physiological and pathological processes. Allosteric mGluR ligands are particularly promising drug targets because of their modulatory effects--enhancing or suppressing the response of mGluRs to glutamate. The mechanism by which this modulation occurs is not known. Here, we propose the hypothesis that positive and negative modulators will differentially stabilize the active and inactive conformations of the receptors, respectively. To test this hypothesis, we have generated computational models of the transmembrane regions of different mGluR subtypes in two different conformations. The inactive conformation was modeled using the crystal structure of the inactive, dark state of rhodopsin as template and the active conformation was created based on a recent model of the light-activated state of rhodopsin. Ligands for which the nature of their allosteric effects on mGluRs is experimentally known were docked to the modeled mGluR structures using ArgusLab and Autodock softwares. We find that the allosteric ligand binding pockets of mGluRs are overlapping with the retinal binding pocket of rhodopsin, and that ligands have strong preferences for the active and inactive states depending on their modulatory nature. In 8 out of 14 cases (57%), the negative modulators bound the inactive conformations with significant preference using both docking programs, and 6 out of 9 cases (67%), the positive modulators bound the active conformations. Considering results by the individual programs only, even higher correlations were observed: 12/14 (86%) and 8/9 (89%) for ArgusLab and 10/14 (71%) and 7/9 (78%) for AutoDock. These findings strongly support the hypothesis that mGluR allosteric modulation occurs via stabilization of different conformations analogous to those identified in rhodopsin where they are induced by photochemical isomerization of the retinal ligand--despite the extensive differences in sequences between mGluRs and rhodopsin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.